Genetically modified porcine cells, tissue, and animals with reduced human xenoreactivity and methods of using the same
US-2024271103-A1 · Aug 15, 2024 · US
US11872253B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11872253-B2 |
| Application number | US-202217724386-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2022 |
| Priority date | Nov 16, 2017 |
| Publication date | Jan 16, 2024 |
| Grant date | Jan 16, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.
Opening claim text (preview).
What is claimed is: 1. Amethod for producing agarotriose, the method comprising: (a) reacting any one substrate of agar, agarose or neoagarohexose with a β-agarase of SEQ ID NO:1 or SEQ ID NO:5; (b) reacting the reaction product of step (a) with a neoagarobiose hydrolase of SEQ ID NO: 2 or SEQ ID NO:6, to make a resulting product comprising agarotriose; and (c) purifying the agarotriose from the resulting product through a size-exclusion column. 2. The method of claim 1 , wherein the β-agarase of SEQ ID NO: 1 is an enzyme that is derived from a Bacteroides plebeius DSM 17135 strain, and that uses agar, agarose, or neoagarohexaose as a substrate to degrade the substrate into neoagarotetraose and neoagarobiose. 3. The method of claim 1 , wherein step (a) is performed at 0 to 200 rpm under a temperature condition of 30 to 60° C. for 5 minutes to 12 hours. 4. The method of claim 1 , wherein the neoagarobiose hydrolase of SEQ ID NO:2 is an enzyme that is derived from a Bacteroides plebeius DSM 17135 strain, and that uses neoagarotetraose or neoagarobiose as a substrate to degrade the substrate into agarotriose, galactose, or 3,6-anhydro-L-galactose. 5. The method of claim 1 , wherein step (b) is performed at 0 to 200 rpm under a temperature condition of 25 to 45° C. for 30 minutes to 12 hours.
Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells · CPC title
containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21) · CPC title
Bacteria or derivatives thereof, e.g. probiotics · CPC title
Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title
Bifidobacteria · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.